Prospective evaluation of the effectiveness of combined treatment of macular edema secondary to retinal vein occlusion with intravitreal bevacizumab and dexamethasone implants

ABSTRACT Purpose: To evaluate the effectiveness of intravitreal bevacizumab injections following a single dexamethasone implant in the treatment of macular edema secondary to branch and central retinal vein occlusion. Methods: This was a prospective interventional non-comparative study, 44 eyes of patients with naïve macular edema related to branch and central retinal vein occlusion were treated with a dexamethasone implant. Patients were followed-up at four-week intervals from the second to the sixth month. If persistent or recurrent macular edema occurred during this period, the patient was treated with intravitreal bevacizumab injections on an as-needed basis. The outcome measures were best-corrected visual acuity and central macular thickness changes. Results: The mean best-corrected visual acuity changed from 0.97 ± 0.33 LogMAR at baseline to 0.54 ± 0.40 at the six-month post-implant examination (p摘要 目的：评估单次玻璃体内地塞米松植入剂注射后，按需予以玻璃体腔内贝伐珠单抗注射治疗分支视网膜静脉阻塞及中央视网膜静脉阻塞继发黄斑水肿的临床疗效。 方法：本研究为前瞻性非对照介入性研究，共纳入44例（44眼）初诊分支视网膜静脉阻塞及中央视网膜静脉阻塞相关黄斑水肿患者，予以玻璃体内地塞米松植入剂治疗。自术后第2个月至第6个月，每4周随访一次；若随访期间出现黄斑水肿持续存在或复发，则按需给予玻璃体腔内贝伐珠单抗注射治疗。本研究的主要结局指标为最佳矫正视力及黄斑中心视网膜厚度变化。 结果：患者基线时最佳矫正视力为0.97±0.33 对数最小分辨角（LogMAR），至植入术后6个月随访时提升至0.54±0.40（p